# China NMPA Drug Inspection - Sichuan Tuojiangyuan Pharmaceutical Co., Ltd. - honeysuckle

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-tuojiangyuan-pharmaceutical-co-ltd/91f394d3-61cc-4bef-a0a1-a278ca74fde2/
Source feed: China

> China NMPA drug inspection for Sichuan Tuojiangyuan Pharmaceutical Co., Ltd. published November 15, 2022. Drug: honeysuckle. On November 15, 2022, the National Medical Products Administration (NMPA) released Announcement No. 55, detailing 19 bat

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 55 of 2022 from the National Medical Products Administration regarding 19 batches of drugs that did not meet the requirements.
- Company Name: Sichuan Tuojiangyuan Pharmaceutical Co., Ltd.
- Publication Date: 2022-11-15
- Drug Name: honeysuckle
- Inspection Finding: Content determination, properties, heavy metals and harmful elements did not meet the requirements
- Action Taken: Risk control measures such as suspending sales and use, recalling products, conducting investigations and rectifications, and initiating investigations.
- Summary: On November 15, 2022, the National Medical Products Administration (NMPA) released Announcement No. 55, detailing 19 batches of pharmaceutical products that failed to comply with national standards. The report identifies 12 companies involved in manufacturing substandard drugs. Notably, Luoyang Shunshi Pharmaceutical Co., Ltd. was cited for eight batches of Jiegu Qili Wan that contained excessive heavy metals and harmful elements. Hainan Huluwa Pharmaceutical Group Co., Ltd. was also identified for a batch of Vitamin U Belladonna Aluminum Capsules II that failed content determination tests. Other companies, including Jiangsu Zhishantang, Hubei Mintai, and Anqing Huashi, were found to have produced substandard honeysuckle and peach kernels due to issues with moisture content, appearance, and chemical composition. These inspections, conducted under the framework of the Drug Administration Law of the People's Republic of China, have prompted immediate regulatory intervention. The NMPA has ordered the relevant enterprises to implement risk control measures, including the suspension of sales, cessation of use, and full product recalls. Furthermore, provincial authorities are required to investigate the root causes of these quality failures, oversee necessary rectifications, and initiate legal proceedings where illegal activity is suspected. The results of these follow-up investigations will be publicly disclosed to ensure consumer safety and industry accountability.

Company: https://www.globalkeysolutions.net/companies/sichuan-tuojiangyuan-pharmaceutical-co-ltd/553679f5-a193-4716-8f6f-6c176561be6b/